Posted by ed_uk on December 15, 2004, at 8:51:35
In reply to An unusual drug: Pirlindole, posted by ed_uk on December 15, 2004, at 8:44:54
Acta Psychiatr Scand. 1996 Dec;94(6):404-10.
A double-blind randomized placebo-controlled study of the efficacy and safety of pirlindole, a reversible monoamine oxidase A inhibitor, in the treatment of depression.
De Wilde JE, Geerts S, Van Dorpe J, Bruhwyler J, Geczy J.
Neuropsychiatric Clinic, St Camillus, Sint-Denijs-Westrem, Belgium.
The efficacy and safety of pirlindole (300 mg/day), a reversible inhibitor of monoamine oxidase A, have been evaluated in a multicentre placebo-controlled double-blind randomized trial in 103 in-patients suffering from unipolar major depression (DSM-III-R 296.2, 296.3) over a 42-day period after a run-in placebo period of 6 days. Pirlindole produced a significantly greater decrease than placebo in the Hamilton depression score (from day 28), the Hamilton anxiety score (from day 28) and the Montgomery-Asberg depression score (on day 42). On day 42, the Hamilton depression score was < or = 7, > or = 8 and < or = 15, or > or = 16 in 21%, 45% and 34%, respectively, in the placebo group compared to 72%, 24% and 3.4%, respectively, in the pirlindole group (P < 0.001). The differences between the two groups in terms of tolerance and safety were not statistically significant.
poster:ed_uk
thread:429814
URL: http://www.dr-bob.org/babble/20041211/msgs/429817.html